FDA approves neratinib for extended adjuvant treatment of early stage HER2-positive breast cancer


 The U.S. Food and Drug Administration approved neratinib (NERLYNX, Puma Biotechnology, Inc.) for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab-based therapy (07/17/2017). Full link